Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation

Basit Öğe Kaydı
dc.authoridHacıbekiroğlu, İlhan/0000-0002-0333-7405
dc.authoridTanriverdi, Ozgur/0000-0002-0598-7284
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridCabuk, Devrim/0000-0002-7871-6311
dc.authorwosidHacıbekiroğlu, İlhan/JCN-7264-2023
dc.authorwosidTanriverdi, Ozgur/M-2172-2015
dc.authorwosidkarabulut, senem/AAT-3594-2020
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.contributor.authorErdogan, Bulent
dc.contributor.authorKodaz, Hilmi
dc.contributor.authorKarabulut, Senem
dc.contributor.authorCinkaya, Ahmet
dc.contributor.authorTozkir, Hilmi
dc.contributor.authorTanriverdi, Ozgur
dc.contributor.authorCabuk, Devrim
dc.date.accessioned2024-06-12T11:07:52Z
dc.date.available2024-06-12T11:07:52Z
dc.date.issued2016
dc.departmentTrakya Üniversitesien_US
dc.description.abstractLung cancer in smokers and non-smokers demonstrates distinct genetic profiles, and cigarette smoking affects epidermal growth factor receptor (EGFR) function and causes secondary EGFR tyrosine kinase resistance. We evaluated the effect of active smoking in patients with metastatic lung adenocarcinoma. A total of 132 metastatic lung adenocarcinoma patients, diagnosed between 2008 and 2013, with known EGFR mutation status, were evaluated retrospectively. Among these patients, 40 had an activating EGFR mutation. Patients who continued smoking during the treatment were defined as active smokers. Former smokers and never smokers were together defined as non-smokers. The outcomes of the treatment in relation to the EGFR mutation and smoking status were evaluated. The median follow-up time was 10.5 months. The overall response rate for the first-line therapy was significantly higher among the EGFR-mutant patients (p = 0.01), however, smoking status had no impact on the response rate (p = 0.1). The EGFR-mutant active smokers progressed earlier than the non-smokers (p < 0.01). The overall survival (OS) of the non-smokers and patients treated with erlotinib was significantly longer (p = 0.02 and p = 0.01, respectively). Smoking status did not affect the OS in EGFR wild type tumors (p = 0.49) but EGFR-mutant non-smokers had a longer OS than the active smokers (p = 0.01). The active smokers treated with erlotinib had poorer survival than the non-smokers (p = 0.03). Multivariate analysis of EGFR-mutant patients showed that erlotinib treatment at any line and non-smoking were independent prognostic factors for the OS (p = 0.04 and p = 0.01, respectively). Smoking during treatment is a negative prognostic factor in metastatic lung adenocarcinoma with an EGFR mutation.en_US
dc.identifier.doi10.17305/bjbms.2016.1380
dc.identifier.endpage285en_US
dc.identifier.issn1512-8601
dc.identifier.issn1840-4812
dc.identifier.issue4en_US
dc.identifier.pmid27371767en_US
dc.identifier.scopus2-s2.0-85013083044en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage280en_US
dc.identifier.urihttps://doi.org/10.17305/bjbms.2016.1380
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22210
dc.identifier.volume16en_US
dc.identifier.wosWOS:000388033500007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAssoc Basic Medical Sci Federation Bosnia & Herzegovina Sarajevoen_US
dc.relation.ispartofBosnian Journal Of Basic Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLung Adenocarcinomaen_US
dc.subjectEpidermal Growth Factor Receptoren_US
dc.subjectSmokingen_US
dc.subjectTyrosine Kinase Inhibitorsen_US
dc.subjectCigarette-Smokingen_US
dc.subjectGene-Mutationsen_US
dc.subjectNever-Smokersen_US
dc.subjectCanceren_US
dc.subjectGefitiniben_US
dc.subjectErlotiniben_US
dc.subjectPharmacokineticsen_US
dc.subjectMetaanalysisen_US
dc.subjectResistanceen_US
dc.titleImpact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu